ProPhase Labs, Inc. (OTC: PRPH) reported its financial results for the year ended December 31, 2025, showing revenue of $4.9 million, a net loss of $13.35 million, and operating expenses of $18.6 million, down $19.3 million from $37.9 million in 2024.
Revenue fell 27.6% from $6.8 million in 2024, driven by a $1.9 million decline in consumer‑products sales and zero revenue from diagnostic services. Gross margin improved to 39.6% in 2025 from a 2.2% loss in 2024, largely due to a higher mix of higher‑margin consumer products and the elimination of diagnostic service revenue.
The Crown Medical Collections initiative remains a key focus, with a $201.2 million gross‑claims portfolio and an estimated net recovery of $50–$60 million after contingency fees. Management said the receivables platform is “accelerating settlement activity” and could generate cash flow beginning in Q3 2026, potentially improving liquidity and enabling debt repayment. “We are very encouraged by the scale and progression of activity across our receivables platform. The level of engagement, the volume of claims in active negotiation, and the early settlement activity we are seeing reinforce our belief that this represents a highly valuable asset,” said CEO Ted Karkus. “Based on current activity and Crown Medical's analysis, we believe this platform has the potential to generate meaningful cash flow beginning in Q3, which could significantly enhance our liquidity position.”
Nebula Genomics/DNA Complete has become operating profitable on a standalone basis following recent cost‑optimization initiatives and restructuring efforts, while the BE‑Smart esophageal cancer diagnostic remains in development with a laboratory‑developed test launch targeted for Q1 2026. These developments position ProPhase to diversify revenue streams beyond its legacy consumer‑product line.
The company’s COVID‑19 testing laboratory subsidiaries filed for Chapter 11 reorganization in September 2025 to advance the Crown Medical Collections initiative. ProPhase has delayed filing its 2025 Annual Report on Form 10‑K, citing the need for additional time for year‑end financial reporting and audit procedures. The stock trades at $0.14 per share.
With no forward guidance disclosed, investors will focus on the company’s ability to convert the Crown Medical Collections receivables into cash, sustain the profitability of Nebula Genomics, and bring the BE‑Smart diagnostic to market. The narrowing net loss and margin improvement signal progress in cost control, but the company remains in a restructuring phase with significant debt and a limited operating cash flow base.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.